- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07349134
WELL-MPN: Цифровое приложение для образа жизни для пациентов с MPN (WELL-MPN)
Пилотное рандомизированное контролируемое исследование цифрового вмешательства для продвижения благополучия, расширения возможностей и обучения здоровому образу жизни у пациентов с миелопролиферативными новообразованиями (WELL-MPN)
The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs).
The main questions it aims to answer are:
Can people with MPNs use the WELL-MPN app?
Does using the WELL-MPN app improve diet quality and physical activity?
Does the WELL-MPN app improve MPN-related symptoms, anxiety and depression, confidence in managing health, and overall quality of life?
Researchers will compare participants who use the WELL-MPN digital app with participants who receive written educational materials about diet and physical activity for people with cancer to see if the app leads to greater improvements in lifestyle behaviors, symptoms, and well-being.
Participants will:
Be randomly assigned to use the WELL-MPN app or receive written lifestyle education materials
Use the assigned program or materials over the study period
Complete surveys about diet, physical activity, symptoms, mood, confidence in self-care, and quality of life
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Chi-Joan How
- Номер телефона: 617-732-5190
- Электронная почта: jhow@bwh.harvard.edu
Места учебы
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02115
- Mass General Brigham
-
Контакт:
- Chi-Joan How
- Номер телефона: 6177325190
- Электронная почта: jhow@bwh.harvard.edu
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Diagnosed with a myeloproliferative neoplasm (MPN) by World Health Organization 2016 criteria
- Adult (age >/= 18)
- Able to comprehend and speak English
- Able to provide informed consent
Exclusion Criteria:
- Unable to comprehend and speak English
- Unable to provide informed consent
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Поддерживающая терапия
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: WELL-MPN Digital App
WELL-MPN app and usual care |
Patients randomized to the WELL-MPN arm will be given access to the WELL-MPN digital program (app) which provides lifestyle counseling through an iPad. |
|
Без вмешательства: Enhanced Usual Care
Usual care and written literature about diet and physical activity guidelines in patients with cancer |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of patients consented and enrolled onto the study, and number of patients who complete at least 2 out of 3 modules in the app.
Временное ограничение: 2 years
|
Primary outcome is feasibility, defined as ≥60% enrollment of eligible patients and ≥70% of patients randomized to the intervention group completing at least 2 out of 3 of app modules. |
2 years
|
|
8-Item Client Satisfaction Scores (CSQ-8)
Временное ограничение: Enrollment to 16 weeks after enrollment
|
Acceptability of WELL-MPN as measured by CSQ-8 scores of WELL-MPN. The CSQ-8 is a self-report tool designed to measure patient satisfaction with a received intervention. It consists of 8 items rated on a 4-point Likert scale (from "quite dissatisfied" to "very satisfied"), with higher scores indicating greater satisfaction. WELL-MPN is considered acceptable if >80% of participants on the WELL-MPN arm report a CSQ-8 score >20. |
Enrollment to 16 weeks after enrollment
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Healthy Eating Index calculated from the Automated Self-Administered Dietary Assessment Tool
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
Diet quality will be compared between control and WELL-MPN patients. The ASA24 is a free 24-hour dietary recall tool developed by the National Cancer Institute. Responses will be used to calculate a Healthy Eating Index (HEI) score, which is a measure of dietary quality that addresses compliance with the 2015 United States Department of Agriculture dietary guidelines (scores range from 0 to 100, with higher scores indicating greater alignment with dietary guidelines). |
Enrollment to 16 weeks after enrollment.
|
|
Mini Eating Assessment Tool (Mini-EAT) score
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
Diet quality will be compared between control and WELL-MPN patients. The Mini-EAT is a 9-item validated brief dietary screener designed for greater ease of administration compared to the ASA-24 but has strong correlation with the HEI. Responses generate a score ranging from 0 to 54, with higher scores reflecting greater adherence to healthy dietary patterns aligned with the Dietary Guidelines for Americans. |
Enrollment to 16 weeks after enrollment.
|
|
Godin Leisure Time Exercise Questionnaire
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
Physical activity will be compared between control and WELL-MPN patients. The Godin Leisure Time Exercise Questionnaire is a brief, self-reported tool used to assess a person's usual physical activity during their free time.It consists of three questions asking information on the number of times one engages in mild, moderate, and strenuous physical activity of at least 15-minute durations in a typical week. Higher scores indicate greater physical activity, with scores of less than 14 units indicating insufficient / sedentary activity. |
Enrollment to 16 weeks after enrollment.
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy Short Forms
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
Self-efficacy will be compared between control and WELL-MPN patients. The PROMIS Self-Efficacy Short Forms include 4-item scales across domains such as managing daily activities, symptoms, medications, emotions, and social interactions. Each item is rated on a 5-point Likert scale, with higher scores indicating greater self-efficacy. |
Enrollment to 16 weeks after enrollment.
|
|
MPN Symptom Assessment Form (SAF) Total Symptom Score (TSS)
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
MPN symptom scores will be compared between control and WELL-MPN patients. The MPN SAF TSS is a 10-item questionnaire assessing the most representative and clinically relevant MPN symptoms (concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, fever), and includes a "worst fatigue" question from the Brief Fatigue Inventory. Each subscale ranges from 0 (absent / as good as it can be) to 10 (worst imaginable / as bad as it can be), and scores are computed as the average of the observed items multiplied by 10 to achieve a 0 to 100 scale. |
Enrollment to 16 weeks after enrollment.
|
|
Hospital Anxiety and Depression Scale (HADS-A and HADS-D):
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
Psychological distress will be compared between controls and WELL-MPN patients. The 14-item HADS consists of two 7-item subscales assessing anxiety and depression symptoms in the past week. Each subscale ranges from 0 (no distress) to 21 (maximum distress), with higher scores indicating worse distress. Subscale scores > 8 indicate clinically significant distress; scores can be further interpreted as follows: 8-10 indicates mild distress, 11-14 indicates moderate distress, and 15-21 indicates severe distress. |
Enrollment to 16 weeks after enrollment.
|
|
Functional Assessment of Cancer - General (FACT-G)
Временное ограничение: Enrollment to 16 weeks after enrollment.
|
Quality of life will be compared between controls and WELL-MPN patients. The FACT-G consists of four subscales assessing well-being across four domains (physical, functional, emotional, and social). Subscale scores include Functional Well-Being (0-28), Social Well-Being (0-28), Emotional Well-Being (0-24), and Functional Well-Being (0-28) with higher scores reflecting better well-being in each domain. |
Enrollment to 16 weeks after enrollment.
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Chi-Joan How, Massachusetts General Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Гематологические заболевания
- Нарушения свертывания крови
- Заболевания костного мозга
- Геморрагические расстройства
- Заболевания тромбоцитов крови
- Новообразования костного мозга
- Гематологические новообразования
- Гемики и лимфатические заболевания
- Тромбоцитоз
- Миелопролиферативные заболевания
- Тромбоцитемия, эссенциальная
- Полицитемия Вера
- Первичный миелофиброз
Другие идентификационные номера исследования
- 25-805
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .